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Abstract
Introduction: Diarrheal diseases are the second leading cause of childhood morbidity and mortality in developing
countries and an important cause of malnutrition. An estimated 0.75 million children below 5 years of age die
from diarrhea. Vomiting associated with acute gastroenteritis (AGE) is a distressing symptom and limits the success
of oral rehydration in AGE leading to an increased use of intravenous rehydration, prolonged emergency
department stay and hospitalization. In this review we estimate the effect of antiemetics in gastroenteritis in
children.
Methods: We conducted a systematic review of all the efficacy and effectiveness studies. We used a standardized
abstraction and grading format and performed meta-analyses for all outcomes with more than two studies. The
estimated effect of antiemetics was determined by applying the standard Child Health Epidemiology Reference
Group (CHERG) rules.
Results: We included seven studies in the review. Antiemetics significantly reduced the incidence of vomiting and
hospitalization by 54%. Antiemetics also significantly reduced the intravenous fluid requirements by 60%, while it
had a non-significant effect on the ORT tolerance and revisit rates.
Conclusion: Antiemetics are effective for the management of gastroenteritis in children and have the potential to
decrease morbidity and mortality burden due to diarrhea, when introduced and scaled up.
Introduction
Approximately 6.9 million deaths of children under five
years occurred in 2011 due to preventable and treatable
causes [1]. Diarrheal diseases are a leading cause of
childhood morbidity and mortality in developing coun-
tries and an important cause of malnutrition. An esti-
mated 0.751 million children below 5 years of age die
from diarrhea and 8 out of 10 of these deaths occur in
the first two years of life [2]. The incidence of diarrhea
has declined from 3.4 episodes/child year in 1990 to 2.9
episodes/child year in 2010 [3] showing that improve-
ments have been observed, but over a greater span of
time.
In 1996, The American Academy of Pediatrics (AAP)
issued a consensus statement that antiemetic drugs were
not recommended in children with gastroenteritis and
healthcare providers should be aware of their potential
side effects [4]. However in 2003, the Centers for Dis-
ease Control (CDC) and Prevention issued a report
which stated that ondansetron could be effective in
decreasing vomiting and limiting hospital admission [5].
This was endorsed by the AAP in 2004 and although
the recommendations do not support the routine use of
pharmacologic therapy, the policy states that, ondanse-
tron may be beneficial in limiting vomiting and hospital
admissions [6]. Similarly, a European guideline stated
that antiemetics might be of value in children with
severe vomiting [7].
Vomiting associated with acute gastroenteritis (AGE)
is a distressing symptom, both for children and their
parents. Furthermore, vomiting limits the success of oral
rehydration in AGE leading to an increased use of intra-
venous (IV) rehydration, need for prolonged emergency
department stays and hospitalizations. Thus despite
being a subject of controversy, a number of antiemetic
agents are now commonly administered worldwide in
an attempt to reduce vomiting in children with AGE.
These include dopamine (D2) antagonists, serotonin or
* Correspondence: zulfiqar.bhutta@aku.edu
1Division of Women & Child Health, The Aga Khan University, Karachi,
Pakistan
Full list of author information is available at the end of the article
Das et al. BMC Public Health 2013, 13(Suppl 3):S9
http://www.biomedcentral.com/1471-2458/13/S3/S9
© 2013 Das et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
5-hydroxytryptamine (5-HT3) antagonists, anticholiner-
gic agents, antihistamines, benzodiazepines, and corti-
costeroids which are administered orally, intravenously
or rectally. Choosing between these therapeutic agents
involves careful consideration of a number of factors,
including effectiveness, side effect profiles and cost. A
national survey conducted in United States of America
(USA) estimates that 61% of physicians would adminis-
ter antiemetics during oral rehydration if they felt it to
be necessary [8]. Another survey carried out in Italy,
reports that 79% of pediatricians use antiemetics to con-
trol vomiting in AGE [9]. Antiemetics such as pro-
methazine, prochlorperazine, and metoclopramide are
known to have serious side effects; hence they are less
commonly prescribed [10]. Recently antiemetics such as
ondansetron have been used in secondary care setting in
pediatric population. A number of randomized control
trials have been carried out to evaluate its efficacy, safety
and cost effectiveness [11-18]. Some researchers have
also used rectal dimenhydrinate [19] and dexamethasone
[20] but the numbers of studies are limited and clear
evidence of any effect on outcomes is yet to be clear.
We conducted a systematic review followed by a
meta-analysis to determine whether antiemetic drug use
in gastroenteritis provides symptomatic relief and
improves other clinically significant outcomes and
whether important adverse effects result from using
these medications. We have reviewed the available lit-
erature and evaluated the quality of included studies
according to the Child Health Epidemiology Reference
Group (CHERG) adaptation of Grading of Recommen-
dations, Assessments, Development and Education
(GRADE) criteria [21]. The review has been designed
according to Lives Saved Tools (LiST) and is therefore
different from the previously done reviews.
Methods
We systematically reviewed all published literature until
January 2012. A search was conducted in Pubmed, Med-
line, Cochrane Libraries, EMBASE and World Health
Organization (WHO) regional databases to identify all
published and unpublished clinical trials, additional stu-
dies were identified through hand search of references
from included studies (figure 1). We used the Medical
Subject Heading Terms (MeSH) and keyword-search
strategy using various combinations of: gastroenteritis,
vomiting, antiemetics and children. No language or date
restrictions were employed in the electronic search. Two
authors independently assessed the eligibility using pre-
defined inclusion and exclusion criteria and performed
data extraction. Any discrepancies between the reviewers
in either the decision of inclusion or exclusion of studies
or in data extraction were resolved by discussion aimed
at reaching consensus.
Inclusion criteria
We limited the inclusion to randomized and quasi-
randomized trials where any antiemetic was adminis-
tered to children with vomiting associated with AGE.
We considered any antiemetic administered orally, intra-
venously or as a suppository at any dosage, prescribed to
terminate or reduce vomiting versus a placebo or nothing.
Our initial objective was to evaluate the effectiveness of
antiemetics in children aged 0 to 5 years presenting with
AGE. However, the literature search did not identify any
studies that provided us with data specific to this age
group; hence we expanded our eligibility to include studies
which had recruited children aged 0 to 12 years. We
excluded studies in which patients had vomiting due to
alternative etiologies, which were done on adults and
which did not have a placebo or a suitable control group.
Abstraction, analysis and summary measure
All the studies that met the final inclusion criteria were
double data abstracted into a standardized form for
each outcome of interest. We extracted the following
details:
1. Study methods: method of allocation, masking of
participants and outcomes, exclusion of participants
after randomization and proportion of losses to follow-
up.
2. Participants: country, sample size, age, inclusion and
exclusion criteria.
3. Intervention: type of antiemetic; dose, frequency
and route.
4. Outcomes: any primary and secondary outcomes.
Each study was assessed and graded according to the
CHERG adaptation of the GRADE technique [21]. Indivi-
dual studies were graded according to strengths and lim-
itations of the study. Studies received an initial score of
high if a randomized or cluster randomized trial and then
the grade was decreased for each study design limitation,
if applicable. A study was downgraded if there were limita-
tions in the conduct of studies e.g. inadequate methods of
sequence generation or allocation concealment and/or
high loss to follow-up (>20%). Risk of bias in the included
studies was assessed according to the latest Cochrane
Handbook. A grade of “high”, “moderate”, “low” and “very
low” was used for grading the overall evidence indicating
the strength of an effect on specific health outcome [21].
Quantitative data synthesis
Outcomes were double data extracted and were analyzed
using RevMan version 5.1. The binary measure for indivi-
dual studies and pooled statistics was reported as the
relative risk (RR) between the experimental and control
groups with 95% confidence intervals (CI). Mantel–
Haenszel pooled RR and corresponding 95% CI were
reported or the DerSimonian–Laird pooled RR and
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corresponding 95% CI where there was an unexplained
heterogeneity.
The weights given to each study were based on the
inverse of the variance. Heterogeneity was quantified by
Chi2 and I2, which can be interpreted as the percentage
of the total variation between studies that is attributable
to heterogeneity rather than to chance, a low p-value
(less than 0.1) or a large chi-squared statistic relative to
its degree of freedom and I2 values greater than 50%
were taken as substantial and high heterogeneity. In
situations of high heterogeneity, causes were explored
by sensitivity analysis and random effect models were
used.
Results
We identified 910 papers from the database search.
After the initial title and abstract screening, 20 full texts
were reviewed to identify papers which met the inclu-
sion criteria and had outcomes of our interest. As no
paper reported data exclusively for the 0-5 years age
group, we expanded our study population to include
children up to 12 years of age. Seven papers [12,13,
15,17-20] met our inclusion criteria and had the out-
come measures of our interest, were finally selected for
abstraction and analysis (table 1). All of these were dou-
ble blind randomized controlled trials that were con-
ducted in developed nations. Six of the seven studies
were conducted in an emergency department (ED) setup
while one [19] was in an outpatient setup and was a
multicenter study. Children analyzed by these studies
varied in age from 5 months to 12 years. Various drugs
were used as antiemetics; four trials used oral ondanse-
tron, one used rectal dimenhydrinate, participants of
one trial were either given IV ondansetron or IV meto-
clopramide, and compared against placebo, while parti-
cipants of one trial were either given IV ondansetron or
IV dexamethasone. None of the studies had isolated the
cause of AGE or stratified results according to causative
agents, although cases with dysentery were excluded
from the trials. To estimate the effectiveness of antie-
metics and its possible role in gastroenteritis, we found
six papers that reported data on vomiting and hospitali-
zation outcomes. Three papers reported on outcomes of
Intravenous fluid (IVF) requirements, oral rehydration
therapy (ORT) tolerance, IVF requirement rates and
admission within 72 hours of discharge from the ED.
Table 2 shows the results and quality assessment of stu-
dies by outcome.
Vomiting
Data on vomiting available from six studies
[12,13,15,17-19] and 830 participants was pooled and
analyzed for this outcome. Results (Figure 2) indicate
that antiemetics were associated with a significant 54%
reduction in the incidence of vomiting (RR: 0.46 95%
CI: 0.35, 0.61). The follow up periods used for this parti-
cular outcome varied across studies. As heterogeneity
was high (Chi2 = 11.92, I2 = 50%, P = 0.06) a random
effect model was used. Sub group analysis based on the
different antiemetics used, showed that oral ondansetron
Figure 1 Search strategy flow diagram
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Uhlig [19] 2009 Germany December
2005 to
May 2007
Children 6 months to 6 years with suspected
infectious gastroenteritis (<24 hours) with mild or
no dehydration, 2 vomiting in 12 hours, > 7kg
Dimenhydrinate Rectal
Suppositories
<15kg 40mg, 15 to

















Children 6 months to 10 years with vomiting or
dehydration as a result of AGE and at least one
episode of nonbilious vomiting, and no severe
dehydration
Ondansetron Oral 8-15kg 2mg, 15-
30kg 4mg, >30kg
8mg
day 3 and day 7
via telephone,
last follow-up till






2002 USA Children 6 months to 12 years with clinically
diagnosed AGE with 5 episodes of vomits in 24
hours
Ondansetron Oral 6 months to 1 year
1.6mg, 1 year to 3
years 3.2mg, 4 to
12 years 4mg








Children 1 to 10 years with AGE and mild to
moderate dehydration who failed controlled oral
challenge in ED
Ondansetron Oral <15kg 2mg, 15 to
23 kg 4mg, >30kg 6
mg
1 week Double Blind,
Prospective




Children aged 6 months to 12 years, with more
than three episodes of vomiting in the past 24
hours, mild/moderate dehydration, and failed oral
hydration. Children with a history or physical
examination findings inconsistent with the




















Children aged 5 months to 8 years who had
nonbillious, nonbloody vomit at least 4 times in
the last 6 hours, who could not tolerate ORT, at
least four episodes of diarrhea in the previous 24
hours, and who had mild-to-moderate
dehydration. Aetiology of acute gastroenteritis
(viral, bacterial or amebic) was not taken into
account in the patients included in the study.
Ondansetron Oral ondansetron 0.2
mg/ kg 8 hourly




1997 Venezuela 6 months to 8 years with spontaneous vomiting






























Table 2 Quality assessment of trials of antiemetics on vomiting and hospitalization rates in acute gastroenteritis
Quality Assessment Summary of Findings
Directness No of events




Intervention Control Relative Risk
(95% CI)
Morbidity-Vomiting: Moderate outcome-specific quality
6
[12,13,15,17-19]
RCT Studies used different follow up
periods. Random effect model
was used
All studies suggest benefit Four of six studies were
conducted in developed
countries
Pooled results for different
types of antiemetics and route
of administration.
95 210 0.46 [0.35, 0.61]
b
4 [13,15,17,18] RCT All studies suggest benefit Three of four studies were
conducted in developed
countries
Effect of oral ondansetron 47 134 0.35 (0.26, 0.46)
a
1 [12] RCT Insignificant effect In developing country Effect of IV ondansetron 5 10 0.50 (0.24, 1.04)
1 [12] RCT Insignificant effect In developing country Effect of IV metoclopramide 8 10 0.80 (0.50, 1.28)
1 [19] RCT In developed country Effect of rectal dimenhydrinate 35 56 0.60 (0.44, 0.82)
Morbidity- Hospitalization rates: Moderate outcome-specific quality
6 [13,15,17-20] RCT All studies suggest benefit.
Fixed effect model used
Five of six studies were
conducted in developed
countries
Pooled results for different
types of antiemetics and route
of administration.
24 56 0.46 [0.29, 0.74]
a
4 [13,15,17,18] RCT All studies suggest benefit Three of four studies were
conducted in developed
countries
Effect of oral ondansetron 11 33 0.36 (0.18, 0.72)
a
1 [20] RCT Developed country Effect of IV ondansetron 2 9 0.21 (0.05, 0.94)
1 [20] RCT Insignificant effect Developed country Effect of IV dexamethasone 7 9 0.73 (0.30, 1.79)
1 [19] RCT Insignificant effect Developed country Effect of rectal dimenhydrinate 4 5 0.77 (0.21, 2.78)
Revisit rates : low outcome-specific quality
4 [13,15,17,18] RCT Variable time periods used in
the four studies
Two studies suggest benefit
while two studies report
otherwise
Three out of four studies
were conducted in
developed countries
All studies used oral
ondasetron
34/284 30/269 0.97 [0.62, 1.53]
a
IVF required rates: Low outcome-specific quality
3 [13,15,17] RCT All studies are consistent in
the results. Fixed effect model
used
All studies were conducted
in developed countries
All studies used oral
ondansetron
35 93 0.40 [0.29, 0.56]
a
ORT tolerance rates: Low outcome specific quality
3 [17,18,20] RCT Random effect model used.
Two of the three studies
suggest benefit
All studies were conducted
in developed countries
Pooled results for different
antiemetics and routes of
administrations
155 125 1.22 [1.01, 1.46]
b
Admission Rates within 72 hours of discharge from ED: Low outcome-specific quality
3 [13,15,17] RCT All studies suggest benefit All studies were conducted
in developed countries
All studies used oral
ondansetron
18 30 0.66 [0.37, 1.19]
IVF requirement Rates within 72 hours of discharge from ED oral ondansetron: low outcome-specific quality
3 [13,15,17] RCT Consistent benefit suggested
by the three studies
All studies were conducted
in developed countries
All studies used oral
ondansetron
49 86 0.57 [0.42, 0.76]
a
a: Fixed Effect Model




















and rectal dimenhydrinate were associated with a signifi-
cant reduction of 65% (RR: 0.35, 95% CI: 0.26, 0.46) and
40% (RR: 0.60, 95% CI: 0.44, 0.82) respectively while IV
ondansetron and metoclopramide had a non-significant
reduction of 50% (RR: 0.50, 95% CI: 0.24, 1.04) and 20%
(RR: 0.80, 95% CI: 0.50, 1.28) respectively although only
one study was analyzed for all the antiemetics except for
oral ondansetron.
Hospitalization
Data from six studies [13,15,17-20] and 963 participants
indicated that there was a significant 54% (RR: 0.46, 95%
CI: 0.29, 0.74) reduction in the incidence of hospitaliza-
tion after the use of antiemetics (figure 3). As heteroge-
neity was low (Chi2 = 6.34, I2 = 5%, P=0.39) a fixed
effect model was used. Subgroup analysis for different
antiemetics showed that oral and IV ondansetron signif-
icantly reduced the incidence of hospitalization by 64%
(RR: 0.36, 95% CI: 0.18, 0.72) and 79% (RR: 0.21, 95%
CI: 0.05, 0.94) respectively. While there was a non-
significant reduction in the incidence of hospitalization
of 23% (RR: 0.77, 95% CI: 0.21, 2.78) and 27% (RR: 0.73,
95% CI: 0.30, 1.79) when rectal dimenhydrinate and IV
dexamethasone were used as antiemetics respectively.
Hospitalization within 72 hours from discharge from the
ED was also reported by three studies and showed that
oral ondansetron had a non-significant 34% (RR: 0.66,
95% CI: 0.37, 1.19) reduction.
Revisit rate
Four studies [13,15,17,18] evaluated the revisit rates with
use of oral ondansetron with a total of 553 participants
and indicated that oral ondansetron reduced the revisit
rates to the ED by a non-significant 3% (RR: 0.97, 95%
CI:0.62, 1.53). There was no significant heterogeneity
and hence a fixed effect model was used for analysis.
IVF requirement rate
IVF requirement rate were analyzed in two ways by the
studies included; first, if the patient required IVF during
Figure 2 Forest Plot for the effect of antiemetics for the treatment of gastroenteritis on incidence of vomiting
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the stay in ED and secondly if the patient required IVF
within 72 hours of discharge from the ED. Three studies
[13,15,17] reported both the outcomes and evaluated
the effect of oral ondansetron on IVF requirement rates.
Based on the analysis from the datasets of these three
studies, oral ondansetron reduced the IVF requirements
during the ED stay by 60% (RR: 0.40, 95% CI: 0.29, 0.56)
and within 72 hours of discharge from ED by 34% (RR:
0.66, 95% CI: 0.37, 1.19). A fixed effect model was used
for analysis as there was low heterogeneity.
ORT tolerance rate
Tolerance to ORT as an outcome was reported by three
studies [17,18,20] and it indicates a significant 22% (RR:
1.22, 95%CI: 1.01, 1.46) increase in tolerance after the use
of antiemetics. Subgroup analysis for different antiemetics
shows that oral ondansetron is associated with a 33%
increase (RR: 1.33 95% CI: 0.98, 1.80), IV ondansetron
with a 29% increase (RR: 1.29 95% CI: 1.01, 1.63) and IV
dexamethasone was associated with a non-significant 8%
reduction (RR: 0.92, 95% CI: 0.67, 1.26) in ORT tolerance
rates.
Recommendation for the LiST model
We applied the CHERG rules for evidence review to the
outcomes assessed for the effect of antiemetics on gas-
troenteritis in children. As there was no data on mortal-
ity; either all-cause or cause specific, we used a severe
morbidity outcome to estimate the effect on mortality.
The six RCTs reported a 54% decrease in hospitalization
rates for about 80 admissions. The results also report a
54% reduction in episodes of vomiting after the use of
antiemetics for 300 episodes of vomiting. As the studies
included did not isolate the specific cause of AGE and
we cannot stratify our data according to type of diarrhea
thus these results are applicable to all cases of AGE,
excluding dysentery. Hence we estimate and propose a
54% reduction in diarrhea related mortality with the use
of antiemetics in cases of diarrhea associated with
vomiting. (see Figure 4)
Discussion
Vomiting continues to be associated with hospitalization,
use of IVF, and significant morbidity among AGE affected
children worldwide. Recently the role of antiemetics for
Figure 3 Forest Plot for the effect of antiemetics for the treatment of gastroenteritis on hospitalizations during ED stay
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controlling vomiting in children has been debated. Clinical
practice guidelines for the treatment of children with gas-
troenteritis recommend supportive care using ORT for
mild to moderate dehydration, without fully endorsing the
use of antiemetic medications to control vomiting. How-
ever in clinical practice, it appears that antiemetics are
widely popular among physicians [8,22].
Our analysis of the effect of antiemetics in gastroenteri-
tis suggests that antiemetics are likely to be beneficial in
children with vomiting. The RCTs included in our study
looked at ondansetron, metoclopramide, dimenhydrinate
and dexamethasone. The administration of oral ondanse-
tron was found to reduce incidence of vomiting, reduc-
tion in hospitalization and IVF requirements while IV
ondansetron was associated with a significant increase in
tolerance to ORT. Rectal dimenhydrinate also signifi-
cantly reduced the incidence of vomiting but has only
been evaluated by a single study. There is insufficient evi-
dence to support the role of IV metoclopramide in chil-
dren with AGE as far as the incidence of vomiting is
concerned but significantly reduced the hospitalization
rates. Rectal dimenhydrinate also significantly reduced
the incidence of vomiting and IV dexamethasone did not
significantly decrease hospitalization rates or increased
tolerance to ORT. The outcomes and recommendation
from the meta-analysis are summarized in table 2 based
on the LiST model suggested by the CHERG reviews of
intervention effectiveness on child survival [23].
Oral ondansetron given as a single dose of 0.1-0.25 mg/kg
[13,17] in the emergency department to children with mild
to moderate dehydration decreases the number of children
with persistent vomiting. It also decreases the number of
children requiring IV rehydration and hospital admissions.
Higher doses have also been used but any added advantage
is not apparent [15]. Oral ondansetron may be useful as an
adjunctive measure to ORT in the outpatient or primary
care setting as well, although no study is available at the
moment to confirm this. Thus, it should be an important
area of future research.
Adverse effects reported with use of ondansetron were
limited to increased mean episodes of diarrhea noticed
in a few studies, although this was statistically non-sig-
nificant. A possible explanation could be the variable
duration of follow-up periods employed by different
researchers, while it would be ideal for researchers to
report the actual output volume of stool rather than the
number of episodes [24], which is usually impractical in
outpatient clinical trials. The use of rectal dimenhydri-
nate was not associated with increased episodes of diar-
rhea or any other major adverse effects [19]. Other
antiemetic medications such as metoclopramide appears
to be less efficacious in the treatment of gastroenteritis
induced vomiting and are associated with more adverse
events than ondansetron.
The cost effectiveness of ondansetron has been
another area of concern. However, an economic analysis
[14] in the USA, the administration of ondansetron to
eligible children would prevent approximately 29,246 IV
insertions and 7,220 hospitalizations annually. It also
reported that at the current average wholesale price, its
routine administration to eligible children would
annually save society US$65.6 million (US$49.1–US
$81.1) and health care payers US$ 61.1 million (US
$46.2–US$76.3).
Currently, online pharmacies charge $20 to $30 per
pill for the brand name Zofran [25]. Although this
Figure 4 Application of standardized rules for choice of final outcome to estimate effect of antiemetics in gastroenteritis
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seems expensive, if taken into the account the fact that
use of single dose of ondansetron reduces IVF require-
ments and admission rates, it may be extremely cost
effective. This might not be the case in developing
countries where a majority of children are treated at
facilities that utilize minimal resources and cannot
afford expensive medications. Hence a very clear evi-
dence of its efficacy and safety should be available
before it could be introduced as a standard of care in
the clinical guidelines, especially for both developing
and underdeveloped countries.
The findings in this systematic review are to a large
extent in agreement with those reported by the Cochrane
reviews [26] and previously done meta-analysis on the
same subject [27-31]. Although we differ from the pre-
viously carried out reviews as we have only included studies
looking at children aged 0 to 12 years and we have evalu-
ated the quality of the studies and the outcomes based on
the LiST model as suggested by CHERG intervention
review process. We have also based our recommendations
on the CHERG intervention review process [21].
A number of limitations can be observed from the
included studies that extend to this review. Firstly the
use of antiemetics was studied in the ED setting only
while the role of oral antiemetics such as oral ondanse-
tron in outpatient or primary care settings is yet to be
evaluated. Other study limitations include that a wide
age range of participants were included by different stu-
dies and there was no widely agreed-on definitions of
the outcome measures (e.g. incidence of vomiting, hos-
pital admission, need for IV rehydration) used by differ-
ent studies and children were included with various
degrees of dehydration.
Currently we need more evidence on safety and effi-
cacy of antiemetics in AGE. A study currently underway
will be assessing the use of ondansetron compared with
domperidone in children [32]. Studies also need to be
done in primary care settings with evaluations of cost
effectiveness especially in developing countries. In the
meantime, recommendations by the CDC focus on
appropriate fluid, electrolyte and nutritional therapy in
all patients [5] and if vomiting continues with the possi-
bility of IV rehydration, clinicians should consider using
oral ondansetron.
Conclusion
Antiemetics are effective for the management of gastro-
enteritis in children and have the potential to decrease
the morbidity and mortality burden due to diarrhea,
when introduced and scaled up.
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